Generer rapport
Virksomhedsform
Aktieselskab
Etableret
1987
Størrelse
Mellemstore
Ansatte
129
Omsætning
930
MDKK
Bruttofortj.
151
MDKK
Primært resultat (EBIT)
37
MDKK
Årets resultat
-111.707.000
DKK
Egenkapital
288
MDKK
Reklamebeskyttet virksomhed
Denne virksomhed er reklamebeskyttet. Det betyder bl.a. at oplysningerne ikke må bruges til reklamehenvendelser. annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
994/1.005
"Bund 10%"
Rang i Danmark
342.762/343.294
"Bund 10%"
Direktion top 3
| Kim M Shaffer 1 | CEO |
| John Joseph Calcagno 2 | Direktør |
Legale ejere top 3
Tegningsregler
Selskabet tegnes af den administrerende direktør i forening med en anden direktør eller af den samlede direktion.
Stamoplysninger baseret på CVR
| Navn | Origio A/S |
| Binavne | Coopersurgical A/S, K-Systems A/S, Kivex Biotec A/S, Medi-Cult A/S, Medicult A/S, Origio Scanlab Equipment A/S Vis mere |
| CVR | 10975077 |
| Adresse | Knardrupvej 2, 2760 Måløv |
| Branche | Forskning og eksperimentel udvikling indenfor bioteknologi [721100] |
| Etableret | 01-07-1987 (36 år) |
| Første regnskabsperiode | 01-07-1987 til 31-12-1988 |
| Virksomhedsform | Aktieselskab |
| Antal ansatte | 110 (årsværk:105) |
| Reklamebeskyttelse | Ja |
| Revisor | Kpmg P/S siden 11-04-2014 |
| Regnskabsperiode | 01-11 til 31-10 |
| Selskabskapital | 162.702.520 DKK 162.702.515 DKK (21-03-2012 - 31-10-2020) 159.723.405 DKK (29-08-2011 - 20-03-2012) 146.473.405 DKK (30-06-2011 - 28-08-2011) 145.828.475 DKK (05-04-2011 - 29-06-2011) 145.578.475 DKK (11-01-2011 - 04-04-2011) |
| Vedtægter seneste | 26-04-2023 |
Medlem af brancherne
- Forskning og eksperimentel udvikling indenfor bioteknologiNACE6 indeholdende 555 virk.
- Forskning og eksperimentel udvikling indenfor naturvidenskab og teknikNACE3 indeholdende 1.757 virk.
- Videnskabelig forskning og udviklingNACE2 indeholdende 2.048 virk.
- Liberale, videnskabelige og tekniske tjenesteydelserNACE1 indeholdende 86.700 virk.
Formål
Selskabets formål er at udvikle, producere og sælge produkter til brug inden for området for human reproduktion og cellekulturer og anden dermed forbunden virksomhed efter direktions skøn.
Regnskab
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
| Omsætning | 929.787 +2% | 909.643 +13% | 808.132 -19% |
| Bruttofortjeneste | 150.748 -19% | 185.823 +8% | 171.775 -28% |
| Årets resultat | -111.707 - | 36.973 +413% | 7.202 -92% |
| Egenkapital | 287.538 -33% | 429.245 -15% | 502.520 +1% |
| Balance | 514.579 -2% | 526.225 -21% | 666.331 -2% |
Ledelsesberetning
Development in activities and financial matters
The results for the year totals t.DKK -111.707 against t.DKK 36.973 last year. Management considers the results for the year satisfactory.
As part of a consolidation strategy in CooperSurgical Companies it was announced in 2019 to move the production of media products from Måløv to Costa Rica in 2021. The majority of the production was transferred in 2021 and the remaining was successfully transferred to Costa Rica in April 2022. Because of the production close in Denmark, it was decided to put the building up for sale. The building was sold with effective date October 1st 2022 for DKK 65 millions. Due to regulatory requirements we will maintain a permanent address at Knardrupvej 2 in Måløv for the next 2 years, in agreement with the new owner of the property.
The Center of Excellence (COE) previously placed in Måløv has been moved to newly rented facilities in Belgium and to the legal entity Origio Benelux B.V. in Netherlands. The close of the production, sale of the property and the move of CoE to Origio Benelux B.V. has let to significant reductions in our fixed assets. Transfer of assets to other entities within the Group has been carried out at NBV and the sale of the property has resulted in a gain of DKK 13.673 thousand which was recognised as other operating income in the income statement.
At 31 October 2021 we recognised an inventory provision of DKK 1.512 thousands to write down inventory that was expected to be scraped to net realisable value. The provision was accurate and covered the balance scrapped in 2022. At 31 October 2022 all inventory has been disposed of. In February 2022 we acquired our Czech distributor and are now making direct sales via a Czech branch. The acquisition resulted in the recognition of an intangible asset of DKK 4.527 thousands related to aquired customers.
Origio A/S has received a tax claim from the Danish Tax Authorities of DKK 115.115 thousand plus accumulated interest of DKK 30.621 thousand. In total claim that amounts to DKK 145.736 thousand is expensed in the financial report 2021/22. The claim relates to sale of IP rights in 2018 and 2019 to group companies. The claim from the Danish Tax Authorities is currently being negotiated as Origio A/S does not agree with the valuation used by the tax authorities. The final outcome of the claim can therefore be significantly different than the provided amount.
The results for the year totals t.DKK -111.707 against t.DKK 36.973 last year. Management considers the results for the year satisfactory.
As part of a consolidation strategy in CooperSurgical Companies it was announced in 2019 to move the production of media products from Måløv to Costa Rica in 2021. The majority of the production was transferred in 2021 and the remaining was successfully transferred to Costa Rica in April 2022. Because of the production close in Denmark, it was decided to put the building up for sale. The building was sold with effective date October 1st 2022 for DKK 65 millions. Due to regulatory requirements we will maintain a permanent address at Knardrupvej 2 in Måløv for the next 2 years, in agreement with the new owner of the property.
The Center of Excellence (COE) previously placed in Måløv has been moved to newly rented facilities in Belgium and to the legal entity Origio Benelux B.V. in Netherlands. The close of the production, sale of the property and the move of CoE to Origio Benelux B.V. has let to significant reductions in our fixed assets. Transfer of assets to other entities within the Group has been carried out at NBV and the sale of the property has resulted in a gain of DKK 13.673 thousand which was recognised as other operating income in the income statement.
At 31 October 2021 we recognised an inventory provision of DKK 1.512 thousands to write down inventory that was expected to be scraped to net realisable value. The provision was accurate and covered the balance scrapped in 2022. At 31 October 2022 all inventory has been disposed of. In February 2022 we acquired our Czech distributor and are now making direct sales via a Czech branch. The acquisition resulted in the recognition of an intangible asset of DKK 4.527 thousands related to aquired customers.
Origio A/S has received a tax claim from the Danish Tax Authorities of DKK 115.115 thousand plus accumulated interest of DKK 30.621 thousand. In total claim that amounts to DKK 145.736 thousand is expensed in the financial report 2021/22. The claim relates to sale of IP rights in 2018 and 2019 to group companies. The claim from the Danish Tax Authorities is currently being negotiated as Origio A/S does not agree with the valuation used by the tax authorities. The final outcome of the claim can therefore be significantly different than the provided amount.
25-04-2023